Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir.
Mohsen HeidarySaeedeh ShariatiShima NourigheimasiMona KhoramiMelika MoradiMoloudsadat MotaharParisa BahramiSousan AkramiVahab Hassan KaviarPublished in: BMC infectious diseases (2024)
The Food and Drug Administration (FDA) has licensed many antiretroviral medications to treat human immunodeficiency virus type 1 (HIV-1), however, treatment options for people with multi-drug resistant HIV remain limited. Medication resistance, undesirable effects, prior tolerance, and previous interlacement incapacity to deliver new drug classes all lead to the requirement for new medication classes and drug combination therapy. Fostemsavir (FTR) is a new CD-4 attachment inhibitor medicine that was recently authorized by the United States FDA to treat HIV-1. In individuals with multidrug-resistant (MDR) HIV-1, FTR is well tolerated and virologically active. According to recent investigations, drug combination therapy can positively affect MDR-HIV. The mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of FTR has been highlighted in this review.
Keyphrases
- human immunodeficiency virus
- antiretroviral therapy
- hiv infected
- multidrug resistant
- hiv positive
- combination therapy
- drug resistant
- hepatitis c virus
- hiv aids
- hiv infected patients
- hiv testing
- men who have sex with men
- acinetobacter baumannii
- south africa
- gram negative
- healthcare
- drug administration
- cystic fibrosis
- risk assessment